Archive: February 03 2021
Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
L-MIND Trial Results Show CD19 Antibody Is Reasonable in R/R DLBCL
During a Targeted Oncology Case Based Peer Perspectives Roundtable event, Loretta J. Nastoupil, MD, discussed the case of a 74-year-old patients with diffuse large B-cell lymphoma.
CAR-T Meeting 2021 | Keynote lectures and BiTE vs CAR-T debate
Nicolaus Kröger, MD, University Medical Center Hamburg, Hamburg, Germany, describes what he is looking forward to from the upcoming European CAR T-cell Meeting 2021, including the keynote lectures from world-renowned leaders in the field, who will present their most recent work and discuss the expected developments in the near future.
Ide-cel in R/R myeloma: patient-reported outcomes and resistance
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the details of a number of studies investigating idecabtagene vicleucel (ide-cel), a BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy, in relapsed/refractory (R/R) multiple myeloma patients.
ZUMA-5: high ORR and CR for R/R iNHL with axi-cel
David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, gives an update on the ongoing Phase II ZUMA-5 trial (NCT03105336) of axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR)-T cell therapy, for patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), including follicular lymphoma and marginal zone lymphoma (MZL).
Ianalumab add-on therapy in CLL patients receiving ibrutinib
Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, discusses a Phase Ib trial (NCT03400176) of ianalumab plus ibrutinib in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib therapy. Ianalumab (VAY736) is an anti-BAFF-R monoclonal antibody that causes antibody-dependent cellular cytotoxicity of B-cells.
DREAMM-2: Effects of belantamab mafodotin on patient reported outcomes in myelom...
Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, shares patient-reported outcomes from the DREAMM-2 study (NCT03525678) of single-agent belantamab mafodotin (belamaf) in relapsed/refractory multiple myeloma.
What are the next steps for CAR-T in myeloma?
Sham Mailankody, MBBS, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the future of CAR-T and cellular therapy for multiple myeloma patients. With no currently approved CAR-T therapy for myeloma, he hopes a major advancement will be FDA approval of a BCMA-targeted CAR-T therapy in the near future.
Magrolimab plus azacitidine in treatment-naïve AML
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses a Phase Ib trial (NCT03248479) of magrolimab, a novel anti-CD47 antibody, plus azacitidine in untreated acute myeloid leukemia (AML) patients unfit for intensive chemotherapy.
First-in-human trial of an anti-BCMA ADC for R/R myeloma
Meletios Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece, discusses the results of a Phase I, first-in-human dose-escalation trial (NCT03489525) of MEDI2228 in patients with relapsed/refractory (R/R) multiple myeloma.